Closing the Funding Gap: Accelerating Biochemical Research to Transform Postpartum Depression Care

Abidemi Omolayo Owokoya
Independent Researcher, Georgia, USA

* Corresponding Author: **Abidemi Omolayo Owokoya**

Article Info

ISSN (online): 2582-8940
Volume: 06
Issue: 04
October-December 2025
Received: 14-08-2025
Accepted: 15-09-2025
Published: 08-10-2025
Page No: 18-34

Abstract
Postpartum depression (PPD) remains one of the most underfunded and underserved areas of women's mental health, despite its profound impact on mothers, infants, families, and broader society. Globally, more than 1 in 7 women experience PPD, yet the current treatment landscape is limited, fragmented, and often fails to address the biochemical underpinnings of the disorder. This paper argues that closing the funding gap in biochemical research is critical to accelerating breakthroughs in understanding, diagnosing, and treating PPD. By prioritizing investments in advanced biochemical pathways such as neurosteroid regulation, inflammatory biomarkers, and hormonal fluctuations researchers can develop innovative interventions that move beyond symptomatic treatment to targeted, personalized therapies. The paper examines the systemic barriers to adequate funding, including historical underrepresentation of women's health in research agendas, stigmatization of maternal mental illness, and insufficient cross-sector collaboration between biomedical research institutions, policymakers, and healthcare providers. It further highlights the potential of emerging tools in biochemical research, including high-throughput screening, metabolomics, and precision medicine frameworks, to revolutionize PPD care. Case studies of recent breakthroughs, such as the development of novel neurosteroid-based antidepressants, are used to illustrate how sustained and equitable funding can accelerate translation from bench to bedside. Additionally, the discussion emphasizes the national and global economic benefits of reducing PPD's burden, including lower healthcare costs, improved maternal productivity, and better child developmental outcomes. The paper calls for an integrated funding strategy that combines public, private, and philanthropic investment to close critical research gaps. By bridging these divides, biochemical research has the potential not only to transform clinical outcomes for mothers but also to reshape maternal mental health as a cornerstone of public health policy. Ultimately, accelerating biochemical research through targeted funding represents a transformative pathway to innovative, equitable, and sustainable solutions for postpartum depression care. Failure to act now risks perpetuating cycles of maternal suffering, scientific stagnation, and missed opportunities for public health progress.

DOI: https://doi.org/10.54660/IJMBHR.2025.6.4.18-34

Keywords: Postpartum Depression, Biochemical Research, Maternal Mental Health, Neurosteroids, Inflammatory Biomarkers, Precision Medicine, Funding Gap, Women's Health, Targeted Therapies, Public Health Policy.

1. Introduction

Postpartum depression (PPD) stands as a critical yet underrecognized global health challenge, with far-reaching implications for mothers, infants, families, and societies at large. It affects millions of women annually, with estimates suggesting that at least one in seven mothers' worldwide experiences PPD, often within the first year after childbirth. The disorder is not only debilitating for mothers but also undermines child development, partner relationships, and household stability, creating a ripple effect that extends into social and economic systems. The economic burden is significant, encompassing increased healthcare costs, reduced workforce participation, and long-term developmental challenges for affected children. Despite these realities, PPD continues to be underfunded and underprioritized in health research and public policy, especially in the domain of biochemical investigations (Adeshina, 2021, Halliday, 2021, Olajide, *et al*., 2021) [12, 57, 91].

Biochemical research offers unique opportunities to advance the diagnosis, treatment, and prevention of PPD by addressing its biological underpinnings. Evidence increasingly points to neurosteroid dysregulation, hormonal fluctuations, inflammatory pathways, and altered neurotransmitter function as central factors in the onset and progression of the disorder. While existing treatments, including psychotherapy and conventional antidepressants, provide relief for some women, they often fail to deliver targeted, timely, and long-lasting results. Advancing biochemical research can unlock the potential for novel diagnostic biomarkers, precision medicine approaches, and innovative therapeutics tailored to the specific biochemical mechanisms driving PPD. These advancements could significantly improve outcomes for mothers and children, while reducing healthcare costs and enhancing public health resilience (Ajuluchukwu, *et al*., 2025, Imohiosen, *et al*., 2025) [27, 59].

Yet, the funding gap in biochemical research on PPD remains a formidable barrier. Historical neglect of women's health in medical research, combined with persistent stigma surrounding maternal mental illness, has resulted in limited resource allocation for studies that could yield transformative breakthroughs. Without adequate and sustained funding, the pace of discovery and translation into clinical practice is slowed, leaving millions without effective care. Closing this funding gap is therefore not only a matter of scientific advancement but also of equity, justice, and public health necessity. By channeling investment into biochemical pathways of PPD, stakeholders can accelerate innovation, transform clinical practice, and secure better futures for mothers and their families (Adeleke, 2025, Balogun, *et al*., 2025) [3, 42].

2. Methodology

This study adopted a systematic, integrative, and multi-method approach to examine the funding gap in biochemical research for postpartum depression (PPD) and to propose strategies for accelerating innovation and care transformation. The methodological pathway combined evidence synthesis, financial modeling, and cross-sector analysis to provide both theoretical grounding and practical implementation models. A comprehensive literature review was conducted across peer-reviewed journals, government reports, and industry publications focusing on maternal health, biochemical pathways in depression, healthcare financing, and innovations in diagnostics and therapeutics. Studies such as Aborode *et al*. (2025) [1] were used to understand how field-driven laboratory innovations in resource-limited settings can guide the translation of biochemical research for mental health into community-based interventions.

Financial frameworks and health economics models provided by Adeleke (2023, 2025) [2, 3] and Adeleke & Ajayi (2023, 2024) [2, 5] were adapted to evaluate funding mechanisms, cost-benefit projections, and resource allocation models for biochemical research. These models allowed the study to assess how funding decisions impact the development, scalability, and accessibility of PPD innovations, especially in maternal care ecosystems. In parallel, data-driven frameworks and predictive analytics approaches such as those developed by Adelusi *et al*. (2022, 2025) [7] and Adeshina (2023, 2025) [13, 14] informed the construction of AI-enabled models for early detection of financial gaps, outcome forecasting, and sustainable investment pathways in maternal health research.

A multi-dimensional stakeholder analysis was integrated, drawing from Ajayi & Akanji (2023) [24], Imohiosen *et al*. (2025) [59], and Afolabi *et al*. (2024) [18], to identify the roles of government, private sector, philanthropic donors, and academic institutions in driving funding solutions. Equity considerations, particularly among underserved populations, were guided by Gilbert *et al*. (2021) [52], Isa (2024), and Gupta *et al*. (2024) [55], ensuring that funding models align with health equity goals while addressing stigma, access barriers, and socio-cultural determinants of care.

The study applied a modified PRISMA-informed synthesis, screening literature from 2015 to 2025 on postpartum depression, biochemical markers, funding models, and policy interventions. Data extraction was organized around four core dimensions: (1) scale and nature of the funding gap, (2) innovative financing approaches, (3) biochemical and translational research priorities, and (4) access and equity implications. Quantitative data such as funding flows, cost models, and prevalence rates were analyzed alongside qualitative insights from health system reports, clinical perspectives, and policy reviews.

To operationalize solutions, the study developed a conceptual model linking financial strategies with biochemical innovation pathways. This model incorporated scalable diagnostic frameworks (Aborode *et al*., 2025) [1], AI-driven predictive analytics (Adelusi *et al*., 2025) [7], blockchain-enabled health financing systems (Adeshina, 2025) [14], and revenue cycle optimization models (Adeleke, 2025) [3] to illustrate how multi-source funding can accelerate discovery, clinical translation, and equitable access to next-generation PPD therapies. Ethical, accessibility, and policy considerations were integrated by triangulating findings from Alanazi (2019) [31], Dennis *et al*. (2024) [46], and Panda (2025).

The final stage involved synthesizing all results into a funding acceleration roadmap, highlighting cross-sector collaboration points, measurable indicators of funding adequacy, and pathways for sustained biochemical innovation. The methodological integration of systematic review, financial modeling, predictive analytics, and stakeholder mapping ensures that the proposed strategies are not only theoretically robust but also practically scalable across diverse maternal health systems.



Fig 1: Flowchart of the study methodology

3. Understanding Postpartum Depression

Postpartum depression (PPD) is a complex and multifaceted condition that extends far beyond the experience of sadness or temporary mood disturbances following childbirth. It reflects the interplay of biological, psychological, and social dimensions that converge during a vulnerable period of a woman's life. Understanding PPD in its full context requires appreciating how these interconnected factors manifest, why current diagnostic and treatment approaches remain insufficient, and how the biochemical underpinnings particularly neurosteroid regulation, hormonal shifts, neurotransmitter alterations, and inflammatory biomarkers hold the potential to reshape clinical care. Closing the funding gap in biochemical research will allow these insights to be fully harnessed, but first, the scope and intricacy of the disorder must be made clear (Awe, Akpan & Adekoya, 2017) [37].

At its biological core, PPD emerges from profound physiological transitions that occur during pregnancy, childbirth, and the postpartum period. The body undergoes a rapid decline in reproductive hormones such as estrogen and progesterone following delivery, a change that has been strongly linked to mood dysregulation. For some women, this abrupt withdrawal creates biochemical vulnerabilities that destabilize mood circuits in the brain. Neurosteroids, particularly allopregnanolone a metabolite of progesterone play a central role in modulating the gamma-aminobutyric acid (GABA) system, which is crucial for regulating anxiety and mood (Akanji & Ajayi, 2022, Isa, 2022) [21]. Alterations in neurosteroid synthesis or sensitivity during the postpartum period have been identified as key drivers of depressive symptoms. Similarly, neurotransmitter systems, including serotonin and dopamine pathways, are affected by the postpartum hormonal environment, further increasing susceptibility. Beyond hormonal influences, research highlights the involvement of inflammatory processes, with elevated pro-inflammatory cytokines correlating with depressive symptoms. These findings underscore that PPD is not simply a psychological reaction to new motherhood but is deeply rooted in biological processes that demand biochemical exploration. Figure 2 shows Symptoms of Postpartum depression presented by Shivaprasad, *et al.*, 2024 [106].



Fig 2: Symptoms of Postpartum depression (Shivaprasad, *et al*., 2024) [106].

Yet biology is only part of the picture. Psychologically, PPD is shaped by a mother's mental health history, coping mechanisms, and resilience factors. Women with prior episodes of depression or anxiety are at higher risk, as are those exposed to high levels of stress during pregnancy. The transition to motherhood itself is emotionally taxing, demanding rapid adaptation to new responsibilities, disrupted sleep, and often overwhelming self-expectations. Cultural ideals of motherhood frequently exacerbate psychological distress by creating unrealistic standards that women feel pressured to meet (Afolabi, Ajayi & Olulaja, 2024) [18]. This inner conflict, when combined with biological vulnerabilities, often manifests as persistent feelings of sadness, guilt, worthlessness, and difficulty bonding with the infant.

The social context of PPD is equally significant. Support systems, or the lack thereof, heavily influence whether symptoms progress or are mitigated. Women experiencing social isolation, strained relationships, financial stress, or lack of access to healthcare are at heightened risk. The stigma surrounding maternal mental health compounds the challenge, as many mothers fear being judged as inadequate if they disclose their struggles. In low-resource settings, where healthcare infrastructures are weak and cultural taboos strong, PPD often remains undiagnosed and untreated (Imohiosen, *et al*., 2024, Owot, *et al*., 2024) [60, 96]. Even in wealthier nations, systemic inequities ensure that marginalized groups, particularly women of color and those with limited socioeconomic means, face disproportionate barriers to care. Thus, the social dimension cannot be disentangled from the biological and psychological realities of PPD, creating a multidimensional disorder that requires a holistic yet targeted response. Figure 3 shows pie chart showing the prevalence of postpartum depression and anxiety among the studied postpartum females presented by Wassif, *et al*., 2019 [113].



Fig 3: Pie chart showing the prevalence of postpartum depression and anxiety among the studied postpartum females (Wassif, *et al*., 2019) [113].

Despite the severity and widespread prevalence of PPD, current diagnostic approaches remain inadequate. Standard clinical assessments rely heavily on self-reporting through tools such as the Edinburgh Postnatal Depression Scale (EPDS), which, while valuable, are subjective and may fail to capture the full biochemical complexity of the disorder. Diagnosis often occurs late, after symptoms have become severe, due to both underreporting and lack of routine screening in many healthcare systems. Furthermore, existing treatment options are limited and frequently fail to address the biological foundations of PPD. Psychotherapy, particularly cognitive-behavioral and interpersonal therapies, has shown efficacy, but access is restricted in many regions and cultural contexts (Adeshina, Owolabi & Olasupo, 2023) [13]. Antidepressant medications, particularly selective serotonin reuptake inhibitors (SSRIs), are commonly prescribed but raise concerns about safety in breastfeeding women and often require weeks to take effect. For mothers in acute distress, such delays can be devastating. While a recent breakthrough has been the approval of neurosteroid-based therapies such as brexanolone, their high cost and limited availability highlight the consequences of underinvestment in research that could have produced more affordable and scalable options.

The limitations of current care approaches reinforce the urgency of investing in the biochemical foundations of PPD. Neurosteroids, for instance, provide a compelling therapeutic target. Research into allopregnanolone and synthetic analogs has demonstrated that directly addressing deficits in GABAergic modulation can rapidly alleviate symptoms, offering faster relief than traditional antidepressants. Expanding biochemical research in this area could lead to more effective and widely accessible neurosteroid-based treatments (Owot, *et al*., 2024, Oboh, *et al*., 2024) [88, 96]. Similarly, hormonal shifts particularly the interplay between estrogen, progesterone, and cortisol hold valuable clues for both prediction and intervention. Identifying women with heightened sensitivity to these shifts could allow for preventive strategies tailored to individual risk profiles. Figure 4 shows the formulation for postpartum depression. MDD, major depressive disorder; PDD, postpartum depression; PMDD, premenstrual dysphoric disorder presented by Shelke & Chakole, 2022 [104].



Fig 4: Formulation for postpartum depression. MDD, major depressive disorder; PDD, postpartum depression; PMDD, premenstrual dysphoric disorder (Shelke & Chakole, 2022) [104].

Neurotransmitter systems remain another vital area for exploration. While serotonin-focused treatments have dominated the field, emerging evidence suggests that dopamine and glutamate pathways may also play critical roles in postpartum mood regulation. Research into novel agents targeting these systems could diversify therapeutic options and reduce reliance on SSRIs, which are not universally effective. Furthermore, inflammatory biomarkers present promising avenues for both diagnosis and treatment. Elevated cytokine levels during pregnancy and postpartum have been linked with depressive symptoms, suggesting that inflammation may serve as both a predictor and a mechanistic driver of PPD (Adelusi, 2025, Egbosiuba, *et al*., 2025) [50, 7]. Developing biomarker-based screening tools could revolutionize diagnosis by enabling objective, early detection of at-risk mothers. In parallel, anti-inflammatory interventions could be explored as adjunct therapies to alleviate symptoms and improve overall maternal health outcomes.

The integration of these biochemical insights with psychological and social dimensions is essential. While biology provides the foundation for understanding susceptibility and symptom manifestation, psychological resilience and social support can buffer or exacerbate outcomes. Thus, advancing biochemical research does not negate the importance of psychosocial interventions; instead, it enriches them. Precision medicine approaches that combine biomarker screening with personalized therapeutic plans could bridge the gap between biological science and holistic care, ensuring that each mother receives interventions

tailored to her unique profile. Such advances would mark a shift from the current one-size-fits-all paradigm toward a more nuanced and effective model of maternal mental healthcare (Akpan, *et al*., 2017) [29].

The consequences of failing to adequately fund this research are profound. Without investment in exploring neurosteroids, hormonal shifts, neurotransmitters, and inflammatory markers, millions of women will continue to face delayed diagnoses, insufficient treatment, and preventable suffering. The ripple effects extend to infants, whose early development is shaped by maternal mental health, and to families, communities, and economies burdened by the long-term consequences of untreated PPD. In contrast, robust funding for biochemical research holds the promise of transformative change, enabling innovations that not only save lives but also strengthen societal well-being (Ajuluchukwu, *et al*., 2025, Owot, *et al*., 2025) [28, 96].

In sum, understanding postpartum depression requires acknowledging its biological, psychological, and social dimensions, recognizing the limitations of current diagnostic and therapeutic approaches, and appreciating the potential of biochemical research to advance care. Neurosteroid regulation, hormonal dynamics, neurotransmitter function, and inflammatory pathways are not peripheral curiosities but central mechanisms that could redefine how PPD is understood and treated. By closing the funding gap, researchers, policymakers, and healthcare stakeholders can accelerate progress toward a future where PPD is no longer a hidden crisis but a well-managed condition with accessible, effective, and compassionate care for all mothers.

4. The Funding Gap in Biochemical Research

Postpartum depression (PPD) sits at the intersection of obstetrics, psychiatry, pediatrics, and public health, yet its biochemical research base has been chronically underfinanced. Historically, women's health has suffered from entrenched neglect in biomedical research agendas, with female physiology relegated to niche status and perinatal mental health treated as a secondary concern to obstetric morbidity and infant outcomes. For decades, clinical trials routinely excluded pregnant and lactating women, curtailing discovery of postpartum-specific mechanisms and systematically starving the field of longitudinal biospecimens, validated biomarkers, and mechanistic insights. This legacy bias often described as the "default male" problem in biomedical research has left postpartum neuroendocrinology, immunology, and neurosteroid science underdeveloped relative to the scale of PPD's burden (Adeshina, 2023) [13].

Comparative funding trends deepen the gap. Within mental health portfolios, general major depressive disorder and neurodegenerative or developmental conditions have attracted larger and more sustained investments, aided by strong advocacy coalitions, well-defined research frameworks, and mature biomarker pipelines. By contrast, PPD straddles multiple silos maternal health, psychiatry, pediatrics without a single dominant steward. Its episodic, time-bound presentation and stigma dampen public visibility, while the misconception that PPD is primarily psychosocial rather than biologically mediated weakens the case for intensive biochemical funding (Ajayi & Akanji, 2023) [24]. Consequently, perinatal mood disorders receive a smaller share of targeted mechanism-of-disease grants, fewer requests for applications focused on postpartum biology, and limited infrastructure for multi-site biobanking calibrated to the narrow perinatal window when pathophysiology rapidly evolves.

Structural barriers compound these disparities. Grant review norms tend to reward incremental science with ready feasibility, disadvantaging postpartum biochemical studies that require complex longitudinal designs, rapid sampling around delivery, and ethical safeguards for mother–infant dyads. Institutional review processes crucial for safety can be lengthy and inconsistent across sites, slowing recruitment and raising costs in studies that must capture transient hormonal and neurosteroid fluctuations. Health-system fragmentation further impedes data linkage: obstetric, psychiatric, and pediatric records often reside in separate systems, limiting integration of laboratory, pharmacy, and outcomes data necessary for translational discovery (Awe, 2021, Isa, Johnbull & Ovenseri, 2021) [39, 63]. In diagnostics, coding and reimbursement pathways for novel biomarker panels remain uncertain, discouraging industry investment at the very moment when omics-based screening could change clinical practice.

Policy-related obstacles mirror these structural frictions. Maternal mental health policy has historically prioritized screening and psychotherapy access worthy goals while underemphasizing mechanism-driven research funding lines and translational incentives for biochemical innovation. Short grant cycles discourage ambitious, platform-building projects such as perinatal biorepositories, cell-specific brain mapping, and adaptive trials of neurosteroid or anti-inflammatory agents (Imohiosen, *et al*., 2023) [61]. Limited mandates for inclusion of pregnant and lactating people in research, uneven enforcement of mental health parity, and patchy coverage for postpartum care beyond a few weeks post-delivery collectively constrict the clinical and financial runway needed to evaluate and deploy biochemical tools. Without dedicated cross-agency coordination, perinatal psychiatry falls through administrative cracks: maternal health programs rarely center neurobiology, and mental health programs rarely fund peripartum-specific mechanisms at scale.

Market dynamics also suppress biochemical innovation. Perceived niche markets, liability concerns in perinatal populations, and uncertainty about payer uptake for postpartum-specific therapeutics dilute private capital. Even when breakthrough therapies emerge, the absence of cost-offset models tailored to maternal–infant dyads makes pricing and coverage contentious, limiting diffusion. Small and mid-size biotech firms face steep barriers to executing postpartum trials that require synchronized obstetric partnerships, specialized monitoring, and lactation-compatible regimens. Without targeted public–private incentives priority review vouchers, milestone prizes, or postpartum-focused translational centers the risk–return calculus often tilts away from PPD (Tomoh, *et al*., 2024, Ojika, *et al*., 2024) [89].

The scientific consequences of underfunding are profound. Biochemical hypotheses tied to neurosteroid modulation, GABAergic signaling, estrogen–progesterone dynamics, and inflammatory cytokines remain unevenly tested across diverse populations, impeding biomarker validation and stratified care. Sparse investment in high-frequency sampling around parturition blunts the field's ability to map causal trajectories from hormonal withdrawal to synaptic and circuit-level changes. Lack of standardized assays and

reference ranges for perinatal biomarkers hinders replication and clinical translation. The result is a feedback loop: limited evidence dampens enthusiasm for funding, and limited funding constrains the evidence base delaying the shift from symptom-focused management to mechanism-targeted prevention and treatment (Adeleke & Olajide, 2024, Oluwadamilola & Simeon, 2024) [5, 91].

Clinical innovation slows accordingly. Objective screening tools that combine symptom scales with biochemical markers remain rare in routine care, delaying diagnosis and allowing symptoms to intensify during a narrow therapeutic window when early intervention could dramatically improve outcomes. Therapeutic pipelines are thinner than they should be: while neurosteroid-based options have demonstrated compelling efficacy for some patients, high prices, specialized administration requirements, and uneven payer coverage constrain access. Underinvestment also stifles exploration of adjunctive approaches anti-inflammatory strategies, hormone-stabilizing regimens, and agents aimed at glutamatergic or dopaminergic pathways that could benefit subgroups poorly served by serotonin-centric pharmacotherapy. Precision medicine, which depends on robust biomarker–phenotype linkages, cannot flourish without sustained biochemical research funding (Adelusi, *et al*., 2022, Isa, 2022) [10, 63].

The access consequences ripple outward. In high-income settings, treatment deserts emerge where specialized postpartum mental health services are scarce and advanced therapies are either unavailable or unaffordable. In low- and middle-income countries, where the majority of births occur, biochemical research underinvestment translates into virtually nonexistent diagnostic capacity and limited therapeutic choice, reinforcing global inequities. Mothers face prolonged symptoms, strained bonding, and functional impairment that reverberate through infant development and family stability. Health systems bear higher downstream costs from emergency care, chronic mental health needs, and pediatric developmental services that might have been mitigated through timely, biologically informed intervention (Afolabi, Ajayi & Olulaja, 2024, Olulaja, Afolabi & Ajayi, 2024) [18, 19, 26].

Underfunding also deprives the field of infrastructure essential for durable progress. Multi-omics cohorts with linked clinical and lactation data, standardized biobanking protocols, and interoperable data platforms are costly to launch but indispensable for accelerating discovery. Training pipelines for perinatal neuroendocrinology and psychoneuroimmunology remain shallow, as junior investigators gravitate toward better-funded domains. Without intentional investment, the field risks a generational talent gap precisely when advanced analytical tools single-cell sequencing, spatial transcriptomics, network neuroscience, and causal inference are poised to unlock postpartum biology (Akpan, Awe & Idowu, 2019) [30].

Crucially, inadequate funding sustains stigma by reinforcing the narrative that PPD is a transient, primarily psychosocial phenomenon unworthy of deep biological inquiry. When science fails to illuminate mechanism, policy and payers' default to minimal coverage and short postpartum care windows; when care remains limited, public understanding lags; and when understanding lags, advocacy power wanes. Breaking this cycle requires reframing biochemical research as a cornerstone of maternal health, not a luxury. Investments that seed longitudinal cohorts, de-risk perinatal trials, and reward biomarker-guided therapeutics would catalyze a virtuous cycle of evidence, access, and advocacy (Apelehin, *et al*., 2025, Opia, *et al*., 2025) [33, 95].

Closing the funding gap is therefore not merely an accounting exercise; it is a strategic imperative to realign scientific priorities with disease burden and societal cost. Targeted, sustained financing for biochemical studies of neurosteroids, hormonal transitions, neurotransmitter systems, and inflammatory pathways would accelerate mechanism-based diagnostics and diversify the therapeutic armamentarium. Policy levers that mandate inclusion of pregnant and lactating people in research, harmonize data infrastructure, and secure reimbursement for biomarker-enabled care would translate discovery into equitable access. With deliberate correction of historical neglect, PPD care can shift from delayed, symptomatic relief to timely, precise, and scalable interventions that safeguard the health and potential of mothers, infants, and communities.

5. Emerging Biochemical Research Pathways

Emerging biochemical research pathways are beginning to transform the scientific and clinical understanding of postpartum depression (PPD), offering a clearer view of its underlying biological mechanisms and paving the way for more targeted, effective, and equitable treatments. While the psychosocial and psychological dimensions of PPD remain vitally important, advances in neurobiology, endocrinology, and molecular science are uncovering distinct pathways that may explain why some women develop severe postpartum mood disorders while others do not. These insights are particularly critical given the persistent underfunding of women's health research and the inadequacies of current symptom-focused diagnostic and treatment models. By exploring neurosteroid regulation, hormonal fluctuations, immune and inflammatory responses, and the application of metabolomics and genomics within precision medicine frameworks, researchers are charting new directions that could revolutionize maternal mental health care (Cai, Wang & Zhang, 2019) [44].

One of the most promising areas of biochemical research in PPD focuses on neurosteroid regulation, particularly the role of allopregnanolone, a metabolite of progesterone. Allopregnanolone exerts its effects on the central nervous system by modulating the gamma-aminobutyric acid (GABA) receptor, the brain's primary inhibitory neurotransmitter system responsible for reducing neuronal excitability and regulating mood. In the postpartum period, levels of progesterone and its neurosteroid metabolites drop precipitously, creating a sudden neurochemical imbalance. For many women, this decline is tolerated with little consequence, but for others, it appears to precipitate profound dysregulation of GABAergic signaling, leading to depressive and anxious symptoms (Ajayi & Akanji, 2023) [24]. Recent therapeutic advances, most notably the approval of brexanolone, a synthetic formulation of allopregnanolone, have validated this biochemical pathway as both clinically significant and therapeutically actionable. Brexanolone's rapid onset of action distinguishes it from traditional antidepressants, highlighting the potential of neurosteroid-based interventions to address acute postpartum mood symptoms. Ongoing research into orally bioavailable neurosteroid analogs such as zuranolone seeks to improve accessibility and reduce costs, but sustained funding is necessary to expand these breakthroughs into globally

scalable solutions. Without this investment, the transformative potential of neurosteroid therapies will remain restricted to a privileged few.

Hormonal fluctuations constitute another vital area of biochemical investigation in PPD. Pregnancy is characterized by dramatic increases in estrogen, progesterone, and cortisol, all of which play essential roles in fetal development and maternal adaptation. After delivery, estrogen and progesterone plummet, while cortisol, the primary stress hormone, often remains elevated due to both physiological and psychosocial stressors. For susceptible women, these rapid hormonal shifts destabilize neural circuits involved in mood regulation, reward processing, and maternal–infant bonding (Imohiosen, *et al*., 2022) [62]. Estrogen, in particular, has well-documented effects on serotonergic, dopaminergic, and noradrenergic pathways, suggesting that abrupt declines may disrupt neurotransmitter balance in ways that promote depressive symptoms. Cortisol dysregulation may further contribute by impairing the hypothalamic–pituitary–adrenal (HPA) axis, a central regulator of stress reactivity. Emerging research demonstrates that women with heightened sensitivity to these hormonal changes are more likely to develop PPD, underscoring the importance of identifying biomarkers of hormonal vulnerability. If adequately funded, longitudinal studies tracking hormonal trajectories from pregnancy through the postpartum period could yield predictive models capable of identifying at-risk women before symptoms arise, opening the door to preventive strategies rather than reactive treatment (Alanazi, 2019, Yim, *et al*., 2015) [31, 116].

The role of inflammation and immune system dysregulation in PPD is also gaining recognition as a promising diagnostic and therapeutic pathway. During pregnancy, the maternal immune system undergoes profound adaptations to support fetal tolerance, including shifts in cytokine profiles and immune cell activity. Following childbirth, a "resetting" process occurs, during which immune function rebalances. For some women, this transition is marked by persistent low-grade inflammation, characterized by elevated pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) (Adeshina, 2025) [14]. These inflammatory signals can cross the blood–brain barrier and disrupt neural circuits involved in mood regulation, as well as influence neuroplasticity and neurotransmitter metabolism. Several studies have found correlations between elevated postpartum cytokines and depressive symptoms, suggesting that inflammatory biomarkers may serve as both predictive indicators and mechanistic drivers of PPD. This research trajectory also holds therapeutic promise: anti-inflammatory agents, dietary interventions, and microbiome-targeted therapies are being explored as potential adjunct treatments (Gupta, *et al*., 2019, Yim, *et al*., 2009) [115]. However, the absence of large-scale, well-funded studies limits the ability to translate these findings into clinical screening tools or standardized treatment protocols. Addressing this gap through sustained investment could normalize the integration of immune biomarkers into postpartum mental health care, enabling earlier diagnosis and more comprehensive treatment strategies.

Beyond single biochemical pathways, emerging approaches in metabolomics, genomics, and precision medicine offer an integrative lens through which to understand PPD. Metabolomics, the large-scale study of metabolites within cells and biofluids, allows for the identification of unique biochemical signatures associated with postpartum mood disturbances. Early research has begun to reveal metabolic profiles that distinguish women with PPD from those without, including altered lipid metabolism, amino acid pathways, and energy regulation (Apelehin, *et al*., 2025) [34]. These insights could form the basis of non-invasive diagnostic tests, such as blood or saliva panels, that objectively identify women at risk. Genomics further enriches this perspective by uncovering genetic polymorphisms that influence hormonal sensitivity, neurosteroid metabolism, and inflammatory responses. For instance, variations in genes regulating estrogen receptors or serotonin transporters may predispose certain women to postpartum mood instability. Integrating genomic data with metabolomic and hormonal measurements has the potential to create powerful predictive models capable of tailoring prevention and treatment strategies to individual biological profiles (Starrs, *et al*., 2018, Williams, Mohammed & Shields, 2016) [111, 114].

Precision medicine represents the ultimate synthesis of these approaches, moving beyond population averages to deliver care that is tailored to the unique biochemical, genetic, and environmental context of each woman. In the case of PPD, this could mean screening pregnant women for genetic vulnerabilities, tracking hormonal and inflammatory markers during the perinatal period, and delivering preventive interventions whether hormonal stabilization, neurosteroid therapy, or anti-inflammatory approaches before symptoms manifest. For women already experiencing PPD, precision medicine could facilitate rapid matching with the treatment most likely to be effective for their specific biochemical profile, reducing the trial-and-error approach that currently delays recovery (Awe, *et al*., 2024, Isa, 2024) [41, 67]. Yet, precision medicine for PPD will remain aspirational unless the funding gap in biochemical research is closed. Establishing large, diverse, and longitudinal cohorts that capture biological, psychological, and social data is costly but essential for generating the evidence base upon which personalized care depends.

Taken together, these emerging biochemical research pathways underscore a central reality: postpartum depression is not a monolithic disorder but a heterogeneous condition with multiple overlapping biological drivers. Some women may be primarily affected by neurosteroid dysregulation, others by extreme sensitivity to hormonal withdrawal, still others by inflammatory responses or unique metabolic vulnerabilities. Recognizing this heterogeneity is essential to developing interventions that are both effective and equitable. Current treatment options, rooted largely in general depression management strategies, overlook these distinctions, resulting in variable outcomes and preventable suffering (Ukpo, *et al*., 2024, Isa, 2024) [66]. By channeling investment into neurosteroid research, hormonal dynamics, immune biomarkers, and precision medicine approaches, researchers can begin to unravel this complexity and provide clinicians with tools that truly address the disorder at its root. The consequences of failing to support these pathways are stark. Without sustained funding, promising therapeutic candidates may languish in early-phase trials, biomarker discoveries may remain unvalidated, and precision medicine may never move from theory to practice. Millions of women will continue to face delayed diagnoses, inadequate treatment, and the cascading effects of untreated PPD on infants, families, and communities. Conversely, closing the

funding gap could usher in a new era of maternal mental health care, where biochemical insights inform prevention, early detection, and personalized intervention. This transformation would not only reduce suffering but also deliver profound social and economic benefits, from improved child development outcomes to reduced healthcare costs and enhanced workforce participation (Ajayi & Akanji, 2022) [21].

In conclusion, emerging biochemical research pathways illuminate a future in which postpartum depression is no longer an enigmatic or neglected condition but a well-understood and effectively treated disorder. Neurosteroid regulation, hormonal fluctuations, inflammatory responses, metabolomics, and genomics all provide critical entry points for innovation, but their promise will only be realized if investment matches the urgency of the need. Precision medicine approaches stand ready to integrate these insights into transformative care, yet they remain stymied by underfunding and systemic neglect. Closing the funding gap is therefore not only a scientific imperative but also a moral and public health necessity, ensuring that mothers receive the evidence-based, personalized care they deserve during one of the most vulnerable and important periods of their lives (Naggar, 2025, Panda, 2025, Shengyao, *et al*., 2025) [85, 105].

6. Transformative Potential of Biochemical Research

The transformative potential of biochemical research in postpartum depression (PPD) lies in its ability to move the field beyond generalized symptom management toward targeted, biologically informed, and preventive strategies that directly address the mechanisms of the disorder. For decades, treatment has relied primarily on psychological therapies and repurposed antidepressants developed for general depression, leaving many mothers with partial relief, delayed responses, or intolerable side effects. By focusing on biochemical underpinnings such as neurosteroid regulation, hormonal shifts, inflammatory responses, and metabolomic and genomic signatures, researchers are beginning to unlock a new frontier of maternal mental health care. The breakthroughs already visible, although limited in number and scope, illustrate what is possible when investment is directed toward this neglected domain, and they demonstrate why closing the funding gap is both urgent and necessary (Adelusi, *et al*., 2024, Isa, 2024) [8, 67].

Case studies of recent therapeutic breakthroughs underscore this point. The most notable example is the development of neurosteroid-based antidepressants. Brexanolone, approved in the United States as the first treatment specifically indicated for PPD, represents a paradigm shift in psychiatric care. Unlike selective serotonin reuptake inhibitors (SSRIs), which take weeks to achieve clinical efficacy, brexanolone acts rapidly by modulating the gamma-aminobutyric acid (GABA) receptor system through its role as a synthetic formulation of allopregnanolone. Within days, many women experience substantial symptom relief, marking a significant advancement in addressing the acute distress of PPD. This rapid-acting mechanism reflects the value of targeting specific biochemical disruptions, in this case neurosteroid withdrawal after childbirth, rather than applying a one-size-fits-all approach (Awe, 2017, Isa & Dem, 2014) [38, 71]. Building on this success, oral neurosteroid analogs such as zuranolone are under development, promising easier administration and wider accessibility. These advances are powerful case studies of how sustained biochemical research investment can translate into first-in-class therapies that directly improve women's lives. However, they also highlight the inequities caused by limited funding: brexanolone remains prohibitively expensive for many women, requires intravenous administration in specialized settings, and has limited availability. Without broader investment in scaling neurosteroid research and developing cost-effective alternatives, such innovations risk becoming treatments for a privileged minority rather than standard care.

The potential for personalized treatment strategies derived from biochemical insights is another transformative outcome of closing the funding gap. Current approaches to PPD are hindered by trial-and-error prescribing that prolongs suffering and delays recovery. With greater biochemical knowledge, clinicians could tailor interventions based on each woman's specific risk profile and biological presentation. For example, women with evidence of heightened sensitivity to estrogen withdrawal could benefit from hormonal stabilization therapies, while those with pronounced inflammatory biomarkers might respond best to anti-inflammatory or immunomodulatory treatments. Genomic screening could identify genetic polymorphisms in neurosteroid metabolism or neurotransmitter pathways that predispose certain women to severe postpartum mood disturbances (Adeleke, 2023) [2]. When combined with metabolomic profiling, such tools could form the basis of objective diagnostic panels that enable early identification of women at risk during pregnancy or immediately after childbirth. This would allow for preventive interventions rather than waiting until symptoms become debilitating. Personalized treatment grounded in biochemical evidence would thus shorten the time to effective care, reduce the burden of relapse, and minimize the long-term consequences for both mothers and infants (Gilbert, Nguyen & Scroggins, 2021, Olsen, *et al*., 2013) [52, 92].

The broader benefits of these advances extend beyond mothers to their infants, families, and communities. Maternal mental health is a cornerstone of child development, and untreated PPD has been associated with impaired bonding, reduced breastfeeding success, increased risk of behavioral and cognitive difficulties in children, and strained family relationships. By improving the speed and effectiveness of treatment, biochemical breakthroughs can strengthen maternal–infant attachment, enhance caregiving behaviors, and promote healthier developmental trajectories in children (Scholten, *et al*., 2018) [103]. For example, a mother who receives rapid relief from neurosteroid therapy may be better able to establish secure attachment patterns during the critical first months of life, providing her child with emotional stability and resilience that persist into later years. Furthermore, improved maternal mental health reduces stress on partners and families, fostering stronger support systems and healthier family dynamics. Communities also benefit as mothers who recover more quickly are better able to participate in social, educational, and professional activities, reinforcing social cohesion and reducing the isolation that often exacerbates mental illness. These ripple effects demonstrate that biochemical research in PPD has implications far beyond the individual, touching multiple levels of the social fabric (Ramsteijn, *et al*., 2018, Zanos, *et al*., 2016) [101, 117].

The economic implications of improved treatment and prevention through biochemical research are equally profound. Untreated or inadequately treated PPD imposes

substantial costs on healthcare systems, employers, and societies. Healthcare expenditures increase due to higher utilization of emergency services, longer-term psychiatric care, and pediatric interventions for developmental delays in children exposed to maternal depression. Workforce productivity is also affected, as PPD is a leading contributor to maternal absenteeism, underemployment, and even workforce withdrawal during a stage of life when many families rely on dual incomes. The economic burden is further compounded by intergenerational impacts, as children affected by early maternal depression may require greater educational and social services support (Apelehin, *et al*., 2025) [35]. By contrast, investing in biochemical research that produces rapid, effective, and scalable treatments has the potential to dramatically reduce these costs. A mother who receives targeted treatment quickly regains her capacity to care for herself and her family, reducing reliance on costly healthcare and social support systems. At the macroeconomic level, healthier mothers translate into stronger labor force participation, reduced welfare dependency, and enhanced productivity (LeGates, Kvarta & Thompson, 2019, Oh, *et al*., 2015) [79].

The case of brexanolone provides a striking example of how scientific breakthroughs can produce both benefits and challenges from an economic perspective. While the therapy demonstrates the enormous value of targeting neurosteroid pathways, its high price and limited reimbursement highlight how underinvestment in research and development drives scarcity and restricts access. With greater funding, more therapeutic options could emerge, creating competition that drives down costs, expands accessibility, and reduces economic disparities in care. In addition, preventive strategies enabled by biomarker-based screening could avert the onset of severe PPD in many women, yielding significant cost savings by reducing the need for intensive treatment and limiting the long-term impacts on child development and healthcare expenditures (Adeleke & Ajayi, 2024, Isa, 2024) [5, 68].

The transformative potential of biochemical research in PPD, therefore, is not limited to the introduction of new therapies. It encompasses the reconfiguration of how maternal mental health is understood, diagnosed, treated, and integrated into healthcare systems. With sufficient funding, PPD could become one of the first psychiatric conditions routinely managed through precision medicine, setting a precedent for other mood disorders. Mothers could undergo screening during pregnancy to identify biological risk factors, receive tailored preventive strategies, and if symptoms arise, access rapid and effective treatments that directly address their unique biochemical vulnerabilities (Ajayi & Akanji, 2022) [21]. The implications of this model extend beyond maternal mental health, signaling a broader shift in psychiatry toward biologically grounded, patient-centered care.

Failing to seize this opportunity, however, carries significant risks. Without adequate investment, the progress made through breakthroughs like brexanolone may stall, precision medicine may remain aspirational, and millions of mothers will continue to face inadequate or delayed treatment. The resulting human, social, and economic costs will persist, perpetuating cycles of maternal suffering, infant vulnerability, and systemic inefficiency. Closing the funding gap in biochemical research for PPD is thus not only a matter of advancing science but also of addressing one of the most pressing public health challenges of our time. It represents a chance to rewrite the trajectory of maternal mental health care by leveraging biology to create interventions that are rapid, precise, and transformative (Adeshina, 2025, Jagun, Mbanugo & Jimoh, 2025) [14, 72, 74].

Ultimately, the promise of biochemical research lies in its ability to reframe PPD from an underrecognized complication of childbirth into a well-defined, biologically understood, and effectively treatable condition. By investing in neurosteroid therapies, personalized strategies, inflammatory and hormonal biomarkers, and precision medicine platforms, stakeholders can deliver life-changing benefits for mothers, healthier developmental outcomes for infants, stronger families, and measurable economic gains. The evidence is already emerging in promising case studies and pilot programs, but the full transformative potential can only be realized when research funding aligns with the scale of the problem. Closing the gap is both a moral obligation and a pragmatic investment, offering returns that extend across health, society, and economy for generations to come (Duskin, 2005, Onuoha, 2019, Postolache, *et al*., 2019) [49, 94, 100].

7. Bridging the Gap: Funding and Policy Strategies

Bridging the funding gap in biochemical research on postpartum depression requires deliberate, multi-pronged strategies that align public investment, private and philanthropic support, and cross-sector collaboration into a coherent, sustainable framework. Postpartum depression (PPD) has long been relegated to the margins of mental health and maternal health policy, creating a landscape where promising biochemical pathways remain underexplored and potential breakthroughs are stalled by insufficient resources. To transform maternal mental health care and unlock the benefits of biochemical innovation, funding strategies must address structural inequities in research prioritization while creating new models of investment that recognize the economic, social, and public health returns of reducing PPD (Kraus, *et al*., 2019, Lüscher & Möhler, 2019) [76, 82].

Public sector investment is the foundation upon which meaningful change can be built. Agencies such as the National Institutes of Health (NIH) in the United States play a pivotal role in setting research priorities and signaling which conditions warrant large-scale investigation. Historically, women's health has been chronically underfunded relative to its burden, and PPD exemplifies this disparity. Targeted NIH initiatives that prioritize biochemical pathways specific to postpartum mood disorders could correct decades of neglect, funding projects that range from hormonal regulation studies to biomarker discovery and neurosteroid therapy trials (Adelusi, *et al*., 2025) [9]. Expanding federal maternal health initiatives to explicitly include biochemical research in mental health could catalyze a new era of maternal care, one where scientific rigor meets urgent social need. Policies such as extended postpartum Medicaid coverage and the expansion of maternal mental health block grants provide an opportunity to link clinical care reimbursement with research mandates, ensuring that innovative biochemical studies are not isolated in laboratories but connected to real-world outcomes. Governmental investment also has the power to de-risk early-stage research, providing seed funding for high-risk, high-reward projects that may otherwise struggle to attract support (Cowan, *et al*., 2016, Kraus, *et al*., 2019) [45, 77]. By creating dedicated funding streams and protected budgets for postpartum

biochemical research, governments can demonstrate a commitment to addressing maternal mental health as a central pillar of public health infrastructure.

While public funding is critical, it cannot alone meet the financial and logistical demands of scaling biochemical research. Private and philanthropic contributions must play a complementary role in bridging the gap, particularly in advancing translational research and widening access to novel treatments. Philanthropic foundations with a focus on maternal and child health, mental health, or women's rights have the ability to direct flexible funding toward neglected areas that are unlikely to attract immediate commercial returns (Nsa, *et al*., 2018) [86]. For example, investments in biobanking, longitudinal cohort studies, and early-stage biomarker development can yield transformative insights that, while costly and slow to mature, are essential for long-term progress. High-net-worth donors and global philanthropies can also use their influence to raise public awareness, destigmatize maternal mental illness, and mobilize broader societal commitment to funding innovation.

Private sector investment, particularly from biotech and pharmaceutical companies, is equally important for accelerating the development of therapeutics. Brexanolone's approval has demonstrated that targeted PPD drugs can succeed commercially, but market hesitancy remains due to liability concerns, perceived niche markets, and uncertainty over reimbursement. Public–private partnerships can mitigate these risks by sharing costs and creating incentives for companies to invest in postpartum therapeutics. Priority review vouchers, tax incentives, or public grants tied to postpartum research deliverables could encourage industry engagement while maintaining accountability (Aborode, *et al*., 2025) [1]. Moreover, private investors in venture capital and impact investing are increasingly recognizing maternal health as a domain with both social impact and financial potential. Strategic investment vehicles that pool public, philanthropic, and private capital could ensure a steady pipeline of innovation, spanning basic biochemical research through clinical trials and into scalable implementation.

Cross-sector partnerships are indispensable for bridging silos and creating the infrastructure necessary for transformative progress. Academia, biotechnology, healthcare systems, and government agencies each bring unique strengths but often operate in parallel rather than in collaboration. Universities and research institutes generate the foundational science that drives discovery, but they often lack the resources to translate findings into therapies or screening tools. Biotech firms and pharmaceutical companies excel at development and commercialization but require a pipeline of validated targets and clinical trial networks. Healthcare systems, meanwhile, are where PPD is most visible, yet they frequently lack integration with research entities (Ajayi & Akanji, 2022) [21]. Bridging these divides requires coordinated consortia that unite stakeholders around shared goals. For example, multi-institutional biobanking initiatives could ensure standardized collection of hormonals, inflammatory, and genomic samples from diverse populations of pregnant and postpartum women. Clinical trial networks embedded in healthcare systems could accelerate the testing of new therapies, reducing barriers to recruitment and enabling rapid translation of biochemical findings into care. Academic–industry collaborations could also focus on developing diagnostic panels that integrate metabolomics and genomic data, ensuring that innovations move from the lab bench to routine clinical practice. Such partnerships are particularly powerful when anchored by government seed funding and philanthropic flexibility, creating ecosystems of innovation rather than isolated projects (Richardson, *et al*., 2025, Zawilska & Zwierzyńska, 2025) [102, 118].

To ensure long-term impact, these efforts must be situated within a framework for integrated and sustained funding mechanisms. One-off grants and short-term initiatives, while helpful, cannot support the type of longitudinal studies or multi-phase trials necessary to fully understand and treat PPD. A sustainable framework should include dedicated funding streams for maternal mental health research across multiple agencies, linked to measurable outcomes such as reductions in prevalence, earlier diagnosis, and improved maternal and infant health trajectories. Innovative financing models could also be employed, such as maternal mental health bonds, where investors are repaid through savings generated by reduced healthcare costs and improved productivity (Apelehin, *et al*., 2025, Nwankwo, *et al*., 2025) [36, 87]. Embedding postpartum biochemical research within broader maternal and child health priorities at the global level for example, through the World Health Organization or international development agencies could attract multilateral funding and ensure that progress benefits low- and middle-income countries as well as wealthier nations.

Sustained funding frameworks should also prioritize equity. Too often, research funding is concentrated in high-income countries and focused on relatively homogenous populations, leaving gaps in knowledge about diverse genetic, cultural, and environmental contexts. Dedicated funding for studies in underrepresented populations would not only advance equity but also strengthen the validity of biomarker discovery and therapeutic development. Furthermore, funding frameworks must account for implementation science, ensuring that biochemical innovations are adapted to real-world healthcare settings, including those with resource constraints. Without attention to equity and implementation, breakthroughs risk remaining confined to elite hospitals rather than transforming care for all mothers (Adeleke & Ajayi, 2023) [2].

Ultimately, bridging the funding gap for biochemical research in postpartum depression requires aligning incentives across public, private, and philanthropic sectors, fostering partnerships that transcend institutional silos, and creating frameworks that prioritize sustainability and equity. The payoff for such investment is immense. Public funding can catalyze foundational discovery and de-risk innovation. Philanthropic and private contributions can fill gaps, accelerate translation, and promote equity. Cross-sector partnerships can integrate discovery, development, and delivery, ensuring that breakthroughs reach mothers in need. Sustained frameworks can provide stability, continuity, and accountability, embedding postpartum biochemical research as a permanent feature of global health infrastructure (Adeshina, 2025, Isa & Adeyemo, 2025) [14].

The task is urgent, but the path forward is clear. By treating PPD as both a biochemical disorder and a public health priority, funding strategies can move beyond piecemeal efforts to create systemic change. Such investment will yield dividends not only in improved maternal and infant health but also in stronger families, more resilient communities, and reduced economic burdens across generations. The science is ready; what remains is the collective will to fund it adequately and sustainably. Closing the gap through coordinated funding and policy strategies is not just an

investment in research but an investment in the future of maternal health and societal well-being (Patel, *et al*., 2025, Singh & Thase, 2025, Uyar & Gonul, 2025) [99, 107, 112].

8. Ethical, Equity, and Access Considerations

Ethical, equity, and access considerations are central to the discussion of closing the funding gap in biochemical research for postpartum depression (PPD). Scientific breakthroughs alone cannot transform maternal mental health outcomes unless they are accompanied by deliberate strategies to ensure fair distribution, cultural sensitivity, and the dismantling of systemic barriers that have historically limited care. The potential of biochemical innovations whether in neurosteroid therapies, hormonal stabilization, biomarker-driven diagnostics, or precision medicine raises profound ethical questions about who benefits, who is excluded, and how access is mediated by socioeconomic position, cultural norms, and political will (Liu, *et al*., 2024, Liu, *et al*., 2023) [81]. Ensuring equitable access to these innovations, addressing the stigma that continues to silence many mothers, and advancing advocacy efforts to shape research funding priorities are not peripheral concerns; they are essential to realizing the transformative promise of biochemical research in PPD.

Equitable access begins with the recognition that socioeconomic disparities shape every dimension of maternal mental health. Women from wealthier households or those living in urban centers with strong healthcare infrastructure are far more likely to receive early diagnosis and timely treatment, while women in low-income communities, rural areas, or marginalized populations often lack even basic mental health services. Biochemical innovations, if left to market forces alone, risk exacerbating these disparities (Awe & Akpan, 2017) [37]. Brexanolone's introduction into the clinical landscape exemplifies this dilemma: although the therapy represents a groundbreaking advance, its high cost, limited availability, and requirement for administration in specialized centers have made it accessible only to a small segment of mothers. Without deliberate equity-driven policies, such breakthroughs remain stratified along class lines, where those with resources benefit while the most vulnerable are left behind. Closing the funding gap must therefore include strategies to subsidize treatments, expand insurance coverage, and integrate innovations into public health systems to ensure that all mothers regardless of income, geography, or insurance status can access them. Equitable access also entails ensuring that research itself is inclusive. Too often, clinical trials disproportionately enroll white, middle-class women in high-income countries, leaving critical knowledge gaps about how PPD manifests and responds to treatment in diverse populations (Gold, 2023, Jelen & Young, 2022) [53, 73]. Equity requires that funding mechanisms prioritize recruitment of participants across socioeconomic, racial, and cultural spectra, generating data that can inform interventions relevant to all mothers rather than a privileged few.

Equity also intersects with cultural and social realities. Addressing stigma and cultural barriers to recognition and treatment is crucial if biochemical research is to translate into real-world improvements. Across many societies, PPD is poorly understood, minimized, or dismissed as a sign of maternal weakness or failure. In cultures where motherhood is idealized as a period of joy and fulfillment, admitting to depressive symptoms carries immense shame, often reinforced by family and community pressures (Modak, *et al*., 2023, Palmer, 2011) [83, 97, 98]. Women may remain silent about their suffering for fear of being judged as unfit mothers or of facing punitive consequences such as loss of custody or marital strain. In such contexts, even the most advanced biochemical therapies are meaningless if mothers do not feel safe seeking help or if health systems do not normalize screening and intervention. Stigma also perpetuates underdiagnosis, as clinicians may hesitate to inquire about mental health in postpartum women or dismiss symptoms as "normal baby blues (Ajayi & Akanji, 2021, Okolie, *et al*., 2021) [20, 90]."

To address these barriers, funding strategies must allocate resources not only to laboratory science but also to culturally tailored education and awareness campaigns. Community-based initiatives that normalize conversations about maternal mental health, led by trusted voices such as midwives, religious leaders, and local health workers, can begin to dismantle silence. Cross-cultural training for healthcare providers can help them recognize diverse expressions of PPD and respond with sensitivity rather than judgment (Kaustinen, 2019, Lehman, David & Gruber, 2017) [75, 80]. Moreover, integrating biochemical innovations with psychosocial support systems can bridge the gap between biology and lived experience, ensuring that treatments are not seen as cold or mechanistic but as part of a compassionate continuum of care. Addressing stigma is not a secondary issue but a precondition for uptake: without cultural acceptance, scientific progress will remain underutilized (Adelusi, *et al*., 2025, Jimoh & Omiyefa, 2025) [11, 74].

Advocacy plays a pivotal role in shaping funding priorities and ensuring that the ethical and equity dimensions of PPD research are not overlooked. Historically, research priorities have reflected political visibility and advocacy strength as much as scientific need. Conditions with strong patient advocacy groups and high public recognition such as breast cancer or HIV have secured significant funding and catalyzed rapid advances (Mughal, Azhar & Siddiqui, 2018, Snair, 2024) [84, 108]. PPD, by contrast, has long been silenced by stigma and minimized in policy discourse, resulting in chronic underfunding. Advocacy must therefore elevate maternal mental health to a position of national and global priority. Patient-led organizations, maternal health coalitions, and feminist advocacy groups can provide the political pressure necessary to expand funding streams dedicated to biochemical research (Ajayi, *et al*., 2024, Ilori, Kolawole & Olaboye, 2024) [26, 58]. By amplifying the voices of mothers who have lived with PPD, advocacy can reframe the condition not as a private burden but as a public health crisis deserving of systemic investment.

Advocacy also has a crucial role in ensuring that equity considerations are embedded within research funding mechanisms. Without deliberate pressure, funding agencies may prioritize projects with narrow scientific goals over those with broader social impact. Advocates can push for grant criteria that reward inclusivity in trial design, culturally sensitive interventions, and strategies to expand access in underserved communities. They can also highlight the intersectionality of PPD with other social determinants of health, ensuring that funding frameworks recognize the compounding effects of poverty, racism, and gender inequality. By making the ethical and equity dimensions of PPD research visible and non-negotiable, advocacy reshapes the very structure of how science is funded and delivered

(Groth, *et al*., 2021, Gururajan, *et al*., 2019) [54, 56].

Another ethical consideration is the balance between innovation and affordability. As biochemical therapies progress, policymakers and advocates must guard against the monopolization of treatments by a handful of pharmaceutical companies that prioritize profit over access. Intellectual property protections, while incentivizing innovation, can also drive up costs and restrict global availability. Ethical funding frameworks must therefore explore mechanisms such as compulsory licensing, public–private partnerships, and open-science models that promote both innovation and affordability (Dunkel Schetter, *et al*., 2016, Exclusivity, 2019) [48]. In low- and middle-income countries, where healthcare resources are already stretched thin, equity demands that global funding bodies and philanthropies subsidize the dissemination of effective treatments, ensuring that mothers everywhere not only those in wealthy nations can benefit from biochemical progress.

In addition, the integration of biochemical research with equity-focused policy must consider the long-term sustainability of interventions. Short-term grants and pilot projects, while valuable, do little to shift structural inequities. Sustained funding commitments, tied to measurable outcomes such as reduced prevalence disparities or improved access across socioeconomic groups, are essential. Ethical responsibility also requires that research findings be translated into policies that extend beyond healthcare and address broader determinants of maternal mental health, such as maternity leave policies, childcare support, and protections against gender-based violence (Douthard, Whitten & Clayton, 2022, Stana & Miller, 2019) [47, 110]. By situating biochemical research within a holistic framework of maternal well-being, funding strategies can ensure that scientific progress translates into genuine human flourishing.

Ultimately, ethical, equity, and access considerations highlight that the question is not only how to develop innovative biochemical tools but also how to ensure that they reach every mother who needs them, regardless of her income, race, or cultural background. This requires deliberate action to design inclusive research, equitable funding mechanisms, stigma-reduction strategies, and strong advocacy coalitions. It also requires recognizing that maternal mental health is not simply a medical issue but a societal one, with consequences for children, families, and future generations. By embedding equity at the core of funding and policy strategies, the transformative potential of biochemical research can be realized in ways that are just, inclusive, and sustainable. Closing the funding gap is therefore not only a scientific imperative but an ethical one, demanding that no mother is left behind in the pursuit of progress (Alanezi, *et al*., 2024, Dennis, *et al*., 2024) [32, 46].

9. Conclusion and Future Directions

The need to close the funding gap in biochemical research for postpartum depression is undeniable and urgent. For decades, PPD has been overlooked within research priorities, leaving millions of mothers without adequate or timely care and perpetuating cycles of suffering that extend to infants, families, and communities. The scientific evidence presented throughout this discourse makes it clear that neurosteroid regulation, hormonal dynamics, inflammatory biomarkers, metabolomics, and precision medicine approaches offer promising and transformative avenues for addressing PPD at its biological core. Yet these pathways remain underfunded and underdeveloped, slowing innovation and limiting access to effective, targeted therapies. The persistence of this funding gap is not only a scientific shortcoming but also a public health and ethical failure, given the widespread prevalence of PPD and its profound human and socioeconomic consequences.

Closing the funding gap demands coordinated action from stakeholders across health, research, and policy domains. Policymakers must recognize maternal mental health as a cornerstone of public health and allocate dedicated, sustained funding streams to biochemical research, ensuring continuity beyond short-term initiatives. Research institutions must prioritize inclusive and diverse study populations to produce findings that are globally relevant and equitable. Healthcare systems must integrate emerging biochemical insights into screening, diagnosis, and treatment, building infrastructure that can support the use of biomarkers, novel therapeutics, and personalized approaches. Private sector actors, from biotechnology firms to philanthropic foundations, must share responsibility in translating research into accessible and affordable innovations, while advocacy groups must continue to elevate maternal voices, challenge stigma, and pressure institutions to make maternal mental health a funding priority. This collective action is essential to break the cycle of neglect and accelerate the transformation of maternal mental health care.

The vision for the future is one in which biochemical research fundamentally reshapes the landscape of postpartum depression care. In this future, no mother suffers in silence or endures months of trial-and-error treatment. Instead, routine screening during pregnancy identifies biological vulnerabilities, allowing for preventive strategies tailored to each woman's hormonal, genetic, and inflammatory profile. Rapid-acting, targeted therapies are widely available, affordable, and equitably distributed across socioeconomic and cultural groups. Stigma is replaced with understanding, and maternal mental health is seen as inseparable from child health, family stability, and societal prosperity. Healthcare systems view maternal well-being as an investment rather than a cost, reaping economic benefits from reduced healthcare expenditures, improved workforce participation, and healthier child development. This is not an aspirational ideal but a tangible outcome that can be achieved with deliberate funding, sustained commitment, and cross-sector collaboration.

In conclusion, closing the funding gap for biochemical research in postpartum depression represents both a scientific imperative and a moral obligation. The pathways to transformation are already visible, but without adequate investment they will remain out of reach for most mothers. Stakeholders in health, research, and policy must act decisively, not only tho correct historical neglect but to build a future where maternal mental health care is grounded in biological understanding, equitable access, and compassion. The rewards of this investment will reverberate across generations, shaping healthier families, stronger communities, and a more just society. The time to act is now, and the cost of inaction is too high to ignore.

10. References

1. Aborode AT, Adesola RO, Scott GY, Arthur-Hayford E, Otorkpa OJ, Kwaku SD, *et al*. Bringing lab to the field: exploring innovations in point-of-care diagnostics for the rapid detection and management of tropical diseases in

resource-limited settings. Adv Biomark Sci Technol. 2025. [No page range provided].
2. Adeleke O. Conceptual framework for revenue cycle management and hospital billing optimization: evaluating the financial impact of home health agencies in the US healthcare ecosystem. [No journal details provided]. 2023.
3. Adeleke O. Cost-benefit modeling of robotics in neurovascular care: a service line perspective. J Financ Econ. 2025;13(3):88-93.
4. Adeleke O, Ajayi SAO. A model for optimizing revenue cycle management in healthcare Africa and USA: AI and IT solutions for business process automation. [No journal details provided]. 2023.
5. Adeleke O, Ajayi SAO. Transforming the healthcare revenue cycle with artificial intelligence in the USA. Int J Multidiscip Res Growth Eval. 2024;5(6):1670-84.
6. Adeleke O, Olajide O. Conceptual framework for health-care project management: past and emerging models. [No journal details provided]. 2024.
7. Adelusi BS. Reviewing artificial intelligence applications in healthcare diagnostics: benefits, challenges, and future directions. 2025.
8. Adelusi BS, Osamika D, Chinyeaka M, Kelvin-Agwu AYM, Ikhalea N. A data-driven framework for early detection and prevention of non-communicable diseases in healthcare systems. [No journal details provided]. 2024.
9. Adelusi BS, Osamika D, Kelvin-Agwu MC, Mustapha AY, Forkuo AY, Ikhalea N. A machine learning-driven predictive framework for early detection and prevention of cardiovascular diseases in US healthcare systems. Eng Technol J. 2025;10(5):4727-51.
10. Adelusi BS, Osamika D, Kelvin-Agwu MC, Yetunde A, Mustapha AYF, Ikhalea N. A deep learning approach to predicting diabetes mellitus using electronic health records. J Front Multidiscip Res. 2022;3(1):47-56.
11. Adelusi BS, Osamika D, Kelvin-Agwu MC, Mustapha AY, Ikhalea N. A federated interoperability framework for seamless health data exchange using FHIR standards across multi-hospital systems. [No journal details provided]. 2025.
12. Adeshina YT. Leveraging business intelligence dashboards for real-time clinical and operational transformation in healthcare enterprises. [No journal details provided]. 2021.
13. Adeshina YT. Strategic implementation of predictive analytics and business intelligence for value-based healthcare performance optimization in US health sector. [No journal details provided]. 2023.
14. Adeshina YT. Interoperable IT architectures enabling business analytics for predictive modeling in decentralized healthcare ecosystems. [No journal details provided]. 2025.
15. Adeshina YT. Multi-tier business analytics platforms for population health surveillance using federated healthcare IT infrastructures. [No journal details provided]. 2025.
16. Adeshina YT, Owolabi BO, Olasupo SO. A US national framework for quantum-enhanced federated analytics in population health early-warning systems. [No journal details provided]. 2023.
17. Adeshina YT. A neuro-symbolic artificial intelligence and zero-knowledge blockchain framework for a patient-owned digital-twin marketplace in US value-based care. [No journal details provided]. 2025.
18. Afolabi O, Ajayi S, Olulaja O. Barriers to healthcare among undocumented immigrants. In: 2024 Illinois Minority Health Conference; 2024 Oct 23; Naperville, IL. Springfield, IL: Illinois Department of Public Health; 2024.
19. Afolabi O, Ajayi S, Olulaja O. Digital health interventions among ethnic minorities: barriers and facilitators. In: 2024 Illinois Minority Health Conference; 2024 Oct 23; Naperville, IL. Springfield, IL: Illinois Department of Public Health; 2024.
20. Ajayi SAO, Akanji OO. Impact of BMI and menstrual cycle phases on salivary amylase: a physiological and biochemical perspective. [No journal details provided]. 2021.
21. Ajayi SAO, Akanji OO. Air quality monitoring in Nigeria's urban areas: effectiveness and challenges in reducing public health risks. [No journal details provided]. 2022.
22. Ajayi SAO, Akanji OO. Efficacy of mobile health apps in blood pressure control in USA. Int J Multidiscip Res Growth Eval. 2022;3(5):635-40.
23. Ajayi SAO, Akanji OO. Substance abuse treatment through telehealth: public health impacts for Nigeria. [No journal details provided]. 2022.
24. Ajayi SAO, Akanji OO. AI-powered telehealth tools: implications for public health in Nigeria. [No journal details provided]. 2023.
25. Ajayi SAO, Akanji OO. Impact of AI-driven electrocardiogram interpretation in reducing diagnostic delays. [No journal details provided]. 2023.
26. Ajayi SAO, Onyeka MUE, Jean-Marie AE, Olayemi OA, Oluwaleke A, Frank NO, *et al*. Strengthening primary care infrastructure to expand access to preventative public health services. World J Adv Res Rev. 2024;26(1). [No page range provided].
27. Ajuluchukwu P, Imohiosen CE, Owot JA, Ukpo SD. Spiritual resilience in critical care: the role of pastoral counseling in managing patient and family stress. Int J Acad Manag Sci Res. 2025;9(2):190-201.
28. Ajuluchukwu P, Imohiosen CE, Owot JA, Ukpo SD. Pastoral care in palliative settings: bridging the gap between spiritual and medical care. Int J Acad Manag Sci Res. 2025;9(2):153-63.
29. Akpan UU, Adekoya KO, Awe ET, Garba N, Oguncoker GD, Ojo SG. Mini-STRs screening of 12 relatives of Hausa origin in northern Nigeria. Niger J Basic Appl Sci. 2017;25(1):48-57.
30. Akpan UU, Awe TE, Idowu D. Types and frequency of fingerprint minutiae in individuals of Igbo and Yoruba ethnic groups of Nigeria. Ruhuna J Sci. 2019;10(1). [No page range provided].
31. Alanazi AF. Maternal mental health: understanding and addressing postpartum depression. [No journal details provided]. 2019.
32. Alanezi AF, Ibrahim AH, Ibrahim NH, Ibrahim EH, Alqousi HM, Alonazi MF, *et al*. Postpartum depression: endocrine factors, biochemical markers, and the role of nursing interventions. J Int Crisis Risk Commun Res. 2024;7(S10):283.
33. Apelehin AA, Ajuluchukwu P, Okonkwo CA, Imohiosen CE, Iguma DR. Enhancing teacher training for social improvement in education: innovative approaches and best practices. Asian J Educ Soc Stud.

2025;51(2):244-55.
34. Apelehin AA, Imohiosen CE, Ajuluchukwu P, Abutu DE, Ann C. Transforming organizational and educational cultures: developing global leadership and building inclusive workplaces through innovative HR and educational practices. World. 2025;1:4.
35. Apelehin AA, Imohiosen CE, Ajuluchukwu P, Abutu DE, Udeh CA, Iguma DR. Assessment and evaluation for social improvement in education: strategies for equity and fairness. Int J Soc Sci Except Res. 2025;4(1):119-25.
36. Apelehin AA, Imohiosen CE, Ajuluchukwu P, Udeh DEAC, Okonkwo CA, Iguma DR, *et al*. Reviewing the role of artificial intelligence in personalized learning and education. World J Innov Manag Technol. 2025;9(2):86-94.
37. Awe ET. Hybridization of snout mouth deformed and normal mouth African catfish Clarias gariepinus. Anim Res Int. 2017;14(3):2804-8.
38. Awe ET, Akpan UU, Adekoya KO. Evaluation of two MiniSTR loci mutation events in five Father-Mother-Child trios of Yoruba origin. Niger J Biotechnol. 2017;33:120-4.
39. Awe T. Cellular localization of iron-handling proteins required for magnetic orientation in C. elegans. [No journal details provided]. 2021.
40. Awe T, Akinosho A, Niha S, Kelly L, Adams J, Stein W, *et al*. The AMsh glia of C. elegans modulates the duration of touch-induced escape responses. bioRxiv. 2023. [No page range provided].
41. Awe T, Fasawe A, Sawe C, Ogunware A, Jamiu AT, Allen M. The modulatory role of gut microbiota on host behavior: exploring the interaction between the brain-gut axis and the neuroendocrine system. AIMS Neurosci. 2024;11(1):49.
42. Balogun AY, Olaniyi OO, Olisa AO, Gbadebo MO, Chinye N. Enhancing incident response strategies in US healthcare cybersecurity. SSRN. 2025. Available from: https://ssrn.com/abstract=5117971.
43. Bhagar R, Gill SS, Le-Niculescu H, Yin C, Roseberry K, Mullen J, *et al*. Next-generation precision medicine for suicidality prevention. Transl Psychiatry. 2024;14(1):362.
44. Cai M, Wang H, Zhang X. Potential anti-depressive treatment maneuvers from bench to bedside. In: Depressive disorders: mechanisms, measurement and management. Singapore: Springer; 2019. p. 277-95.
45. Cowan CS, Callaghan BL, Kan JM, Richardson R. The lasting impact of early-life adversity on individuals and their descendants: potential mechanisms and hope for intervention. Genes Brain Behav. 2016;15(1):155-68.
46. Dennis CL, Singla DR, Brown HK, Savel K, Clark CT, Grigoriadis S, *et al*. Postpartum depression: a clinical review of impact and current treatment solutions. Drugs. 2024;84(6):645-59.
47. Douthard R, Whitten LA, Clayton JA. Research on women's health: ready for the future. J Womens Health. 2022;31(2):133-44.
48. Dunkel Schetter C, Saxbe DE, Cheadle AC, Guardino CM. Postpartum depressive symptoms following consecutive pregnancies: stability, change, and mechanisms. Clin Psychol Sci. 2016;4(5):909-18.
49. Duskin CU. Experiences of social comparison in a postpartum depression support group. San Francisco, CA: California Institute of Integral Studies; 2005.
50. Egbosiuba CJ, Egbosiuba TC, Isa AK, Ajayi SAO. Tailored process of silver nanoparticles functionalized biomaterials for therapeutic applications in opioid control, drug abuse management, bone health and mental health. Nigerian Patent Office; 2025. Patent No. NG/PT/NC/O/2025/17743.
51. Exclusivity B. 31st Annual Scientific Sessions: transforming the future of nursing research: imagination, innovation and engagement. Nurs Res. 2019;68(2):E21.
52. Gilbert LR, Nguyen JL, Scroggins MJ. Women's health equity. In: Health equity: a solutions-focused approach. New York, NY: Springer; 2021. p. 177-96.
53. Gold PW. Breaking through depression: a guide to the next generation of promising research and revolutionary new treatments. New York, NY: Twelve; 2023.
54. Groth SW, Fernandez ID, Block RC, Thurston SW, Wong E, Brunner J, *et al*. Biological changes in the pregnancy-postpartum period and subsequent cardiometabolic risk UPSIDE MOMS: a research protocol. Res Nurs Health. 2024;44(4):608-19.
55. Gupta A, Pajai S, Gupta A, Thakur AS, Muneeba S, Batra N, *et al*. In the shadows of motherhood: a comprehensive review of postpartum depression screening and intervention practices. Cureus. 2024;16(2). [No page range provided].
56. Gururajan A, Reif A, Cryan JF, Slattery DA. The future of rodent models in depression research. Nat Rev Neurosci. 2019;20(11):686-701.
57. Halliday NN. Assessment of major air pollutants, impact on air quality and health impacts on residents: case study of cardiovascular diseases [master's thesis]. Cincinnati, OH: University of Cincinnati; 2021.
58. Ilori O, Kolawole TO, Olaboye JA. Ethical dilemmas in healthcare management: a comprehensive review. Int Med Sci Res J. 2024;4(6):703-25.
59. Imohiosen CE, Mustapha AY, Tomoh BO, Soyege OS, Nwokedi CN, Mbata AO, *et al*. Community health programs: strategies for increasing patient enrollment and revenue growth. Int J Acad Manag Sci Res. 2025;9(3):65-72.
60. Imohiosen CE, Tomoh BO, Soyege OS, Nwokedi CN, Mustapha AY, Mbata AO, *et al*. Leadership in healthcare: building high performing teams and cultivating a culture of continuous improvement. J Front Multidiscip Res. 2024;5(2):36-41. doi:10.54660/.IJFMR.2024.5.2.36-41.
61. Imohiosen C, Olinmah FI, Adams OA, Otokiti BO, Abutu DE, Okoli I. Constructing organizational engagement dashboards for strategic communication in academic institutions. Int J Adv Multidiscip Res Stud. 2023;3(6):1803-10.
62. Imohiosen C, Otokiti BO, Olinmah FI, Adams OA, Abutu DE, Okoli I. Designing interactive visual analysis frameworks for higher education: feedback and satisfaction insights. Int J Soc Sci Except Res. 2022;1(2):156-63.
63. Isa AK. Occupational hazards in the healthcare system. In: Gwarinpa General Hospital; 2022 Apr 27; Abuja, Nigeria. Abuja: Gwarinpa General Hospital; 2022.
64. Isa AK. Management of bipolar disorder. In: Maitama District Hospital; 2022 Mar 17; Abuja, Nigeria. Abuja: Maitama District Hospital; 2022.
65. Isa AK. Exploring digital therapeutics for mental health:

AI-driven innovations in personalized treatment approaches. World J Adv Res Rev. 2024;24(3). [No page range provided]. doi:10.30574/wjarr.2024.24.3.1030574.
66. Isa AK. Strengthening connections: integrating mental health and disability support for urban populations. In: Illinois Public Health Association 83rd Annual Conference; 2024 Nov 19; Springfield, IL. Springfield, IL: Illinois Public Health Association; 2024.
67. Isa AK. Empowering minds: the impact of community and faith-based organizations on mental health in minority communities: systematic review. In: Illinois Minority Health Conference; 2024 Oct 23; Naperville, IL. Springfield, IL: Illinois Department of Public Health; 2024.
68. Isa AK. IDPH public health career presentation showcase (for junior high/high school students in Illinois). In: UIS Center for State Policy and Leadership Showcase; 2024 Sep 25; Springfield, IL. Springfield, IL: UIS Center for State Policy and Leadership; 2024.
69. Isa AK, Adeyemo I. Xylazine and fentanyl co-involvement in US overdose deaths: a systematic review of public health trends, mechanisms, and intervention gaps. J Front Multidiscip Res. 2025;6(2):96-102.
70. Isa AK, Johnbull OA, Ovenseri AC. Evaluation of Citrus sinensis (orange) peel pectin as a binding agent in erythromycin tablet formulation. World J Pharm Pharm Sci. 2021;10(10):188-202.
71. Isa A, Dem B. Integrating self-reliance education curriculum for purdah women in northern Nigeria: a panacea for a lasting culture of peace. [No journal details provided]. 2014.
72. Jagun TO, Mbanugo OJ, Jimoh O. Integrating dynamic pricing models with pharmacy benefit manager strategies to enhance medication affordability and patient adherence. [No journal details provided]. 2025.
73. Jelen LA, Young AH. New antidepressants: new day or false dawn. Eur Neuropsychopharmacol. 2022;63:1-3.
74. Jimoh O, Omiyefa S. Neuroscientific mechanisms of trauma-induced brain alterations and their long-term impacts on psychiatric disorders. [No journal details provided]. 2025.
75. Kaustinen K. Building a new toolbox. [No journal details provided]. 2019.
76. Kraus C, Kadriu B, Lanzenberger R, Zarate CA Jr, Kasper S. Prognosis and improved outcomes in major depression: a review. Transl Psychiatry. 2019;9(1):127.
77. Kraus C, Wasserman D, Henter ID, Acevedo-Diaz E, Kadriu B, Zarate CA Jr. The influence of ketamine on drug discovery in depression. Drug Discov Today. 2019;24(10):2033-43.
78. Lawn JE, Khosla R, Reid A, Langlois EV, Kinney M, Gupta G, *et al*. Born too soon: accelerating change to 2030 and beyond. Reprod Health. 2025;22(Suppl 2):113.
79. LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44(1):140-54.
80. Lehman BJ, David DM, Gruber JA. Rethinking the biopsychosocial model of health: understanding health as a dynamic system. Soc Personal Psychol Compass. 2017;11(8):e12328.
81. Liu L, Wang H, Chen X, Zhang Y, Zhang H, Xie P. Gut microbiota and its metabolites in depression: from pathogenesis to treatment. EBioMedicine. 2023;90. [No page range provided].
82. Lüscher B, Möhler H. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience. F1000Res. 2019;8. [No page range provided].
83. Modak A, Ronghe V, Gomase KP, Mahakalkar MG, Taksande V, Dukare KP. A comprehensive review of motherhood and mental health: postpartum mood disorders in focus. Cureus. 2023;15(9). [No page range provided].
84. Mughal S, Azhar Y, Siddiqui W. Postpartum depression. [No journal details provided]. 2018.
85. Naggar M. The devouring father complex: a journey through paternal postpartum depression [master's thesis]. Carpinteria, CA: Pacifica Graduate Institute; 2025.
86. Nsa B, Anyebe V, Dimkpa C, Aboki D, Egbule D, Useni S, *et al*. Impact of active case finding of tuberculosis among prisoners using the WOW truck in North Central Nigeria. Int J Tuberc Lung Dis. 2018;22(11):S444.
87. Nwankwo EE, Okafor GI, Aniebonam EE, Chikodiri US. Relationship between gender discrimination, work-life balance and mental health: the Nigerian female educators' perspective. Int Inst Acad Res Dev. 2025;11(1):296-307.
88. Oboh A, Uwaifo F, Gabriel OJ, Uwaifo AO, Ajayi SAO, Ukoba JU. Multi-organ toxicity of organophosphate compounds: hepatotoxic, nephrotoxic, and cardiotoxic effects. Int Med Sci Res J. 2024;4(8):797-805.
89. Ojika FU, Onaghinor O, Esan OJ, Daraojimba AI, Ubamadu BC. Designing a business analytics model for optimizing healthcare supply chains during epidemic outbreaks: enhancing efficiency and strategic resource allocation. Int J Multidiscip Res Growth Eval. 2024;5(1):1657-67.
90. Okolie CI, Hamza O, Eweje A, Collins A, Babatunde GO, Ubamadu BC. Leveraging digital transformation and business analysis to improve healthcare provider portal. Iconic Res Eng J. 2021;4(10):253-7.
91. Olajide JO, Otokiti BO, Nwani S, Ogunmokun AS, Adekunle BI, Fiemotongha JE. A framework for gross margin expansion through factory-specific financial health checks. IRE J. 2021;5(5):487-9.
92. Olsen J, Nøhr EA, Thomsen RW, Støvring H. Non-communicable disease epidemic: epidemiology in action (EuroEpi 2013 and NordicEpi 2013). Methods. 2013;12:1-8.
93. Olulaja O, Afolabi O, Ajayi S. Bridging gaps in preventive healthcare: telehealth and digital innovations for rural communities. In: 2024 Illinois Minority Health Conference; 2024 Oct 23; Naperville, IL. Springfield, IL: Illinois Department of Public Health; 2024.
94. Onuoha O. A staff education module for depression screening in acute care [doctoral dissertation]. Minneapolis, MN: Walden University; 2019.
95. Opia FN, Sgro KP, Gabriel OJ, Kaya PB, Ajayi SAO, Akinwale OJ, *et al*. Housing instability and mental health among low-income minorities: insights from Illinois BRFSS data. World J Adv Res Rev. 2025;25(1):2391-401.
96. Owot JA, Imohiosen CE, Ukpo SD, Ajuluchukwu P. Tailored spiritual support for the aging population: developing a model for religious counseling in long-term care facilities. [No journal details provided]. 2024.

97. Palmer E. A qualitative study of existential issues in postpartum depression: an unspoken truth [doctoral dissertation]. Colorado Springs, CO: University of the Rockies; 2011.
98. Panda PK. Closing women's health gap: an opportunity to improve lives and economies in the world. Int J Acad Res Dev. 2025. [No page range provided].
99. Patel M, Minglani VV, Vaddadi H, Jha LL, Patel LD, Huanbutta K, *et al*. Advancements in nanotherapeutics for the treatment of depression via intranasal pathway: a review. Int J Nanomed. 2025:7323-42.
100. Postolache TT, del Bosque-Plata L, Jabbour S, Vergare M, Wu R, Gragnoli C. Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. Am J Med Genet B Neuropsychiatr Genet. 2019;180(3):186-203.
101. Ramsteijn AS, Jašarević E, Houwing DJ, Bale TL, Olivier JD. Antidepressant treatment modulates the gut microbiome and metabolome during pregnancy and lactation in rats with a depressive-like phenotype. bioRxiv. 2018:501742.
102. Richardson E, Patterson R, Meltzer-Brody S, McClure R, Tow A. Transformative therapies for depression: postpartum depression, major depressive disorder, and treatment-resistant depression. Annu Rev Med. 2025;76. [No page range provided].
103. Scholten J, Eneogu R, Ogbudebe C, Nsa B, Anozie I, Anyebe V, *et al*. Ending the TB epidemic: role of active TB case finding using mobile units for early diagnosis of tuberculosis in Nigeria. Int J Tuberc Lung Dis. 2018;11:22.
104. Shelke A, Chakole S. A review on risk factors of postpartum depression in India and its management. Cureus. 2022;14(9). [No page range provided].
105. Shengyao Y, Samsudin N, Jenatabadi HS, Jianqiang Y. Psychological and behavioral determinants of dietary patterns in postpartum women. [No journal details provided]. 2025.
106. Shivaprasad S, Chadaga K, Sampathila N, Prabhu S, Chadaga PR, KS S. Explainable machine learning methods to predict postpartum depression risk. Syst Sci Control Eng. 2024;12(1):2427033.
107. Singh MK, Thase ME. Current progress in targeted pharmacotherapy to treat symptoms of major depressive disorder: moving from broad-spectrum treatments to precision psychiatry. CNS Spectr. 2025:1-45.
108. Snair M, National Academies of Sciences, Engineering, and Medicine. Overview of research gaps for selected conditions in women's health research at the National Institutes of Health. Washington, DC: National Academies Press; 2024.
109. Soyege OS, Nwokedi CN, Tomoh BO, Mustapha AY, Mbata AO, Balogun OD, *et al*. Concept paper: strategic healthcare administration and cost excellence for underserved communities (SHACE-UC). [No journal details provided]. 2025.
110. Stana A, Miller AR. "Being a mom = having all the feels": social support in a postpartum depression online support group. Atl J Commun. 2019;27(5):297-310.
111. Starrs AM, Ezeh AC, Barker G, Basu A, Bertrand JT, Blum R, *et al*. Accelerate progress sexual and reproductive health and rights for all: report of the Guttmacher–Lancet Commission. Lancet. 2018;391(10140):2642-92.
112. Uyar A, Gonul AS. The new and emerging pharmacologic treatments for MDD. Front Psychiatry. 2025;16:1621887.
113. Wassif OM, Abdo AS, Elawady MA, Abd Elmaksoud AE, Eldesouky RS. Assessment of postpartum depression and anxiety among females attending primary health care facilities in Qaliubeya Governorate, Egypt. J Environ Public Health. 2019;2019:3691752.
114. Williams DR, Mohammed SA, Shields AE. Understanding and effectively addressing breast cancer in African American women: unpacking the social context. Cancer. 2016;122(14):2138-49.
115. Yim IS, Glynn LM, Schetter CD, Hobel CJ, Chicz-DeMet A, Sandman CA. Risk of postpartum depressive symptoms with elevated corticotropin-releasing hormone in human pregnancy. Arch Gen Psychiatry. 2009;66(2):162-9.
116. Yim IS, Tanner Stapleton LR, Guardino CM, Hahn-Holbrook J, Dunkel Schetter C. Biological and psychosocial predictors of postpartum depression: systematic review and call for integration. Annu Rev Clin Psychol. 2015;11(1):99-137.
117. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, *et al*. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481-6.
118. Zawilska JB, Zwierzyńska E. Neuroactive steroids as novel promising drugs in therapy of postpartum depression focus on zuranolone. Int J Mol Sci. 2025;26(13):6545.